(Colorectal Cancer) Pertuzumab Plus Trastuzumab — Objective Response Rate 32%
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
HER2-Targeted Therapy: Pertuzumab Plus Trastuzumab in HER2-Amplified Metastatic Colorectal Cancer
- May 31, 2019
- Reading time: 1 minute
Objective Response Rate of 32% with Pertuzumab Plus Trastuzumab in HER2-Amplified Metastatic Colorectal Cancer
On March 8, 2019, a Phase 2 clinical trial evaluating the efficacy and safety of the anti-HER2 monoclonal antibody combination of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in patients with HER2-amplified metastatic colorectal cancer who had received multiple prior lines of therapy was published in the medical journal The Lancet Oncology.
Trial Design
This Phase 2 trial administered treatment to patients every 3 weeks, with the treating physician evaluating objective response rate.
Background: Given established evidence of efficacy of anti-HER2 antibodies pertuzumab and trastuzumab in HER2-positive breast cancer, gastric cancer, and other solid tumors, this trial was conducted based on the hypothesis that these agents might also benefit patients with HER2-amplified metastatic colorectal cancer.
Results
Efficacy: Among patients with HER2 amplification, the objective response rate (ORR) was 32%.
Safety: Most common adverse events: diarrhea, fatigue, and nausea. Less common adverse events: hypokalemia and abdominal pain. No treatment-related deaths occurred.
Based on the trial results, heavily pretreated patients with HER2-amplified metastatic colorectal cancer demonstrated acceptable tolerability and meaningful antitumor activity with this combination therapy.
Source: Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, Published: March 08, 2019.
Tags: #ColorectalCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4